Rifaximin is a Small Molecule owned by Alfasigma, and is involved in 35 clinical trials, of which 29 were completed, and 6 are ongoing.

Rifaximin binds to the beta-subunit of bacterial DNA-dependent RNA polymerase, inhibiting bacterial RNA synthesis and bacterial cell growth. This results in the blockage of the translocation step that normally follows the formation of the first phosphodiester bond, which occurs in the transcription process.

The revenue for Rifaximin is expected to reach a total of $29.6bn through 2038. This change impacts the valuation of this asset and is an important factor to understand the current value of the drug in a clinical process. View the complete picture with the Rifaximin NPV Report.

Rifaximin was originated by Alfa Wassermann and is currently owned by Alfasigma. Bausch Health Companies is the other company associated in development or marketing of Rifaximin.

Rifaximin Overview

Rifaximin (Xifaxan / Normix / Spiraxin / Normiks / Refero / Targaxan / Tixteller / Zaxine / Faxinorm / Xifaxanta / Redactiv / Tixtar / Rifacol / Rifxima / Alpha Normix Forte / Flonorm) is a non-aminoglycoside semi-synthetic antibiotic acts as anti-bacterial agent. It is formulated as tablets, film coated tablets, suspension and granules for oral route of administration and ointment and cream for topical application. It is indicated for the treatment of patients with travellers’ diarrhoea (TD) caused by noninvasive strains of Escherichia coli and reduction in risk of overt hepatic encephalopathy. Xifaxanta tablets are indicated for the treatment of travellers' diarrhoea that is not associated with any of fever, bloody diarrhoea, eight or more unformed stools in the previous 24 h and occult blood or leucocytes in the stool. Zaxine is indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in patients greater than18 years of age, adjunct in the treatment of hyperammonemia, and also indicated for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.

The drug candidate is under development for the treatment of Crohn's disease, collagenous colitis, chronic intestinal pseudo-obstruction, Alzheimer's disease, sickle cell disease and symptoms of gastrointestinal distress and pulmonary compromise associated with COVID-19 infection caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and for nonalcoholic fatty liver disease.

It was under development for the treatment of irritable bowel syndrome, decompensated cirrhosis and bacterial vaginosis.

Bausch Health Companies Overview

Bausch Health Companies (Bausch Health), formerly Valeant Pharmaceuticals International Inc, is engaged in the manufacturing, development, and marketing of a range of medical devices, over-the-counter products (OTC), and pharmaceutical products. Bausch Health offers products for therapy areas related to dermatology, gastroenterology, eye health, neurology, aesthetic devices, dentistry, and consumer health. It offers various generic and branded generic products. Bausch Health has administrative, research and laboratory, marketing, distribution, and warehousing facilities worldwide. The company offers products directly or indirectly in various regions across the world including the US, Canada, Africa, Middle East, Australia, Latin America, and Europe. It also operates manufacturing facilities in the US, Brazil, Columbia, Germany, Canada, among others. Bausch Health is headquartered in Laval, Quebec, Canada.

The company reported revenues of (US Dollars) US$8,434 million for the fiscal year ended December 2021 (FY2021), an increase of 5.1% over FY2020. In FY2021, the company’s operating margin was 4.6%, compared to an operating margin of 7.7% in FY2020. The net loss of the company was US$948 million in FY2021, compared to a net loss of US$560 million in FY2020. The company reported revenues of US$2,046 million for the third quarter ended September 2022, an increase of 4% over the previous quarter.

Quick View – Rifaximin

Report Segments
  • Innovator (NME)
Drug Name
  • Rifaximin
Administration Pathway
  • Oral
  • Topical
  • Vaginal
Therapeutic Areas
  • Central Nervous System
  • Gastrointestinal
  • Hematological Disorders
  • Infectious Disease
Key Companies
  • Sponsor Company: Alfasigma
  • Originator: Alfa Wassermann
Highest Development Stage
  • Marketed

GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

To create this model, GlobalData takes into account factors including patent law, known and projected regulatory approval processes, cash flows, potential applicable patients, drug margins, company expenses, and pricing estimates. Combining these data points with GlobalData’s world class analysis creates high value models that companies can use to help in evaluation processes for each drug or company.

The rNPV method integrates the probability of a drug reaching a clinical stage into the cash flow at that time, which provides a more accurate rNPV, as it considers the probability that the drug never makes it through the clinical pathway to commercialization. GlobalData’s rNPV model uses proprietary likelihood of approval (LoA)and phase transition success rate(PTSR) data for the indication in the highest development stage, which can be found on GlobalData’s Pharmaceutical Intelligence Center.